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Abstract
A critical issue in understanding Huntington's disease (HD) pathogenesis is how the ubiquitously
expressed mutant huntingtin (mhtt) with an expanded polyglutamine repeat can cause selective
toxicity of striatal and cortical neurons. Two potential cellular models may contribute to such
specificity: expression of mhtt in these vulnerable neurons alone may be sufficient to result in their
dysfunction and/or degeneration (cell-autonomous model); or mhtt in other cell types can elicit
pathological cell-cell interactions to cause the vulnerable neurons to become dysfunctional and be
at risk for degeneration (cell-cell interaction model). To distinguish between these two models, we
have selectively expressed a neuropathogenic fragment of mhtt-exon1 in striatal medium spiny
neurons (MSNs) by crossing a conditional mouse model of HD with a striatal-specific Cre mouse
line. In this striatal model of HD, we observed progressive and cell-autonomous nuclear
accumulation of mhtt aggregates in MSNs. Surprisingly, unlike the mouse model expressing mhtt-
exon1 in all the neurons in the brain, the striatal model lacks significant locomotor deficits and
striatal neuropathology including gliosis and dark degenerating neurons. Electrophysiological
findings from acutely dissociated MSNs revealed a cell-autonomous deficit in N-methyl-d-aspartate
(NMDA) receptor sensitivity to Mg2+, a deficit also present in other mouse models of HD. In
conclusion, this study provides the first in vivo genetic evidence that pathological cell-cell
interactions are necessary for striatal pathogenesis in a conditional mouse model of HD, and
suggests a ''two-hit'' hypothesis in which both cell-autonomous toxicity and pathological cell-cell
interactions are critical to HD pathogenesis.
Background
Huntington's disease (HD) is an autosomal dominant
neurodegenerative disorder characterized clinically by
movement abnormalities (i.e. chorea), psychiatric symp-
toms, and cognitive deficits [1]. HD belongs to a group of
neurodegenerative disorders caused by polyglutamine
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tion encoding the polyQ repeat lies in exon 1 of the
mutant huntingtin gene: the normal repeat is less than 36
while the mutant repeat ranges from 36 to about 120
[2,3]. In all polyglutamine disorders including HD, the
polyQ repeat length is inversely correlated with the age of
onset of symptoms [4-8].
A critical question in understanding pathogenesis of HD
as well as other polyQ disorders is how the widely
expressed mutant polyQ protein can cause highly selective
neuronal toxicity. In each polyQ disorder, distinct subsets
of neurons in the CNS are selectively affected. The most
affected neuronal type in HD is the striatal medium spiny
neuron (MSN), with the vast majority of MSNs degenerat-
ing in the advanced stage of the disease. The second most
affected neuronal population in HD is the cortical pyram-
idal neuron (CPN), particularly those that lie in the deep
cortical layers [9,10]. Contrary to the significant neurode-
generation in the striatum and cortex, neurons in the cer-
ebellum and other sub-cortical brain regions are usually
spared in the majority of HD patients. The latter brain
regions may exhibit some neurodegeneration only in the
most severely affected, juvenile-onset HD patients who
have relatively longer polyQ repeats [11]. Since mutant
huntingtin (mhtt) is ubiquitously expressed in the brain
and peripheral tissues [11-13], the selective pattern of
neuronal toxicity in HD cannot be explained by the
expression pattern of mhtt [14-17].
Conceptually, there are at least two cellular models that
could account for the selective neuronal toxicity in HD. In
the first, cellular toxicity of mhtt within the vulnerable
neurons alone is sufficient to elicit progressive dysfunc-
tion and degeneration of these neurons (cell-autonomous
model). In the second, pathological cell-cell interactions
elicited by mhtt expression in other cell types are neces-
sary or even sufficient to cause the dysfunction and degen-
eration of the vulnerable neurons (cell-cell interaction
model). Full length mhtt as well as its toxic N-terminal
fragments, which are known to be generated by proteoly-
sis [9,18-21], can elicit a variety of cell-autonomous toxic-
ities including synaptic dysfunction, defective
endocytosis, axonal transport deficits, mitochondria
abnormalities, and transcriptional dysregulation [22].
Recent studies also suggest that mhtt can generate patho-
logical cell-cell interactions including aberrant corticostri-
atal neurotransmission [23], abnormal glial function
[24], and reduction of cortical brain derived neurotrophic
factor (BDNF) [25] which is neurotrophic to MSNs [26].
Despite the rich literature demonstrating the presence of
both cell-autonomous toxicity and pathological cell-cell
interactions in HD models, their relative contributions to
disease pathogenesis remain poorly defined.
To begin to experimentally address this issue we have
developed a Cre/LoxP conditional mouse model of HD
(termed RosaHD mice) in which expression of a neu-
ropathogenic fragment of mhtt (mhtt-exon1), driven by
the endogenous ubiquitously-expressing Rosa26 pro-
moter, can be switched on by Cre recombinase (Fig. 1A;
also ref. [27]). By crossing the RosaHD mouse with the
cortex-specific Emx-1 Cre mouse (cortical model) or the
pan-neuronal Nestin-Cre mouse (pan-neuronal model),
we have obtained direct genetic evidence that cortical
pathogenesis in the HD mice requires pathological cell-
cell interactions. We found robust locomotor deficits and
cortical (and striatal) pathology, including gliosis, dark
neuron degeneration and dystrophic neurites, are only
observed in the pan-neuronal model but not in the corti-
cal model of HD, despite accumulation of mhtt aggregates
in CPNs in both models. Electrophysiological analyses of
these models revealed a deficit in cortical inhibition likely
due to cortical interneuron dysfunction, suggesting that
these interneurons may contribute to cortical pathogene-
sis in HD [27].
In the current study, we used the RosaHD model to
address whether pathological cell-cell interactions are
required for striatal pathogenesis in vivo. By crossing
RosaHD mice with Dlx5/6-Cre mice, we have selectively
switched on mhtt-exon1 expression in all striatal MSNs
and a subset of cortical interneurons. We found that pro-
gressive nuclear accumulation of mhtt aggregates in the
striatum is a cell-autonomous process, but the striatal
model lacks the locomotor deficit and significant striatal
neuropathology which are evident in the pan-neuronal
model of HD. However, electrophysiological analyses
revealed that both the striatal model and pan-neuronal
model exhibit cell-autonomous dysfunctions in NMDA
receptor-mediated responses. The present analyses dem-
onstrate that pathological cell-cell interactions are
required for striatal pathogenesis in the RosaHD mouse
model. Furthermore, our regionally-specific HD mice sup-
port a "two-hit" hypothesis in which both cell-autono-
mous toxicity and abnormal cell-cell interactions
contribute to HD pathogenesis in vivo.
Results
Generation of the striatal model of HD
To selectively express mhtt-exon1 in striatal MSNs, we
crossed RosaHD mice with the well-characterized Dlx5/6-
Cre mice, which have been shown to mediate LoxP
recombination in striatal MSNs, and in a subset of cortical
and olfactory interneurons during embryonic develop-
ment between E11 and P0 [28,29]. To demonstrate the
regional specificity of mhtt-exon1 expression in the
RosaHD/Dlx5/6-Cre (termed the striatal model), we per-
formed immunostaining in 6 month old double trans-
genic mice with the EM48 antibody, a rabbit polyclonalPage 2 of 11
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Generation of the striatal specific mouse model of HDFigure 1
Generation of the striatal specific mouse model of HD. (A) Schematics illustrate the strategy to use cell-type-specific 
Cre to selectively activate mhtt-exon1 expression in all neurons in the brain (pan-neuronal model), only in CPNs (cortical 
model; [27]), and only in striatal MSNs and a subset of interneurons (asterisks) in the cortex (striatal model). (B) Immunohisto-
chemical staining using polyclonal EM48 antibody, which is specific to aggregated forms of mhtt [9], reveals a cell-autonomous 
accumulation of nuclear mhtt aggregates in the striatum of the striatal model at 6 months of age. Inset in B shows at a higher 
magnification the EM48 staining in the nucleus is consisted of diffuse nuclear staining, and not large nuclear inclusions or smaller 
microaggregates. (C) EM48 staining reveal strong nuclear staining in the striatum (str) but sparse nuclear staining in the cortex 
(cor), inset in C shows diffuse EM48 nuclear staining of one cell at high magnification. cc: corpus callosum. Finally, there is no 
nuclear EM48 staining in other brain regions including cerebellum (D) and brain stem (E). Scale bars are 50 μm except in B (200 
μm) and insets in B and C (10 μm).
Molecular Neurodegeneration 2007, 2:8 http://www.molecularneurodegeneration.com/content/2/1/8antibody raised against the N-terminal of human htt
which is highly specific to the aggregated forms of mhtt in
HD patients and HD mouse brains [9]. Consistent with
our prior observation that mhtt aggregation in the
RosaHD cortical and pan-neuronal models is a cell-auton-
omous process, we detected selective accumulation of
EM48 mhtt, in the form of diffuse nuclear staining but not
large nuclear inclusions, in the striatum of the striatal
model (Fig. 1B). There were a few cells with EM48 diffuse
nuclear staining in the cortex (Fig. 1C), but little EM48
nuclear staining was detected in other brain regions
including the cerebellum (Fig. 1D) and brain stem (Fig.
1E), etc. EM48 (+) staining was not observed in wildtype
(WT) littermate controls or in the striatal model in at 1
month of age (data not shown), demonstrating that the
diffuse nuclear accumulation of EM48 (+) mhtt in the
striatum is a cell-autonomous and progressive process in
the striatal model of HD.
To further determine the specificity and extent of mhtt-
exon1 expression in MSNs in the striatal, cortical and pan-
neuronal models of HD, we performed double immun-
ofluorescent staining using EM48 and Darpp-32, a marker
for striatal MSNs in 6 month old mice [30]. We observed
greater than 96% of the MSNs in the striatal model and
99% of MSNs in the pan-neuronal model also were posi-
tive for EM48 (out of more than 200 randomly chosen
Darpp-32 positive cells for each genotype), while none of
the MSNs in the cortical model or WT controls were posi-
tive for EM48 (Fig. 2 and data not shown). Consistent
with the prior observation that Dlx5/6-Cre is expressed in
the cortical interneuron precursors [27], we found that a
subset of cortical GABA positive interneurons also accu-
mulated EM48 (Fig. 2B), but none of the CPNs accumu-
lated EM48 positive nuclear mhtt aggregates in the striatal
model (data not shown). In summary, our analyses
revealed that the striatal model of HD selectively expresses
mhtt in the vast majority of striatal MSNs, and further-
more, the process of mhtt nuclear accumulation and
aggregation is also cell-autonomous in this model.
Lack of significant motor deficits and striatal pathology in 
the striatal model of HD
We next compared the severity of the motor deficits and
striatal neuropathology between the pan-neuronal model
and the striatal model. Our prior analyses showed that the
pan-neuronal model exhibits locomotor hypoactivity at 6
months, striatal gliosis onset at 6 months and dark neu-
ron degeneration at 12 months [27]. In the current study,
we used the same battery of tests to evaluate the striatal
model. To our surprise, these mice did not exhibit any
locomotor deficits at either 6 or 12 months (Fig. 3). Fur-
thermore, we did not detect significant gliosis or dark neu-
rons up to 12 months of age (Fig. 4). Since striatal
expression of mhtt-exon1 is comparable in the two mod-
els driven by the same endogenous Rosa26 promoter, as
demonstrated by EM48 nuclear accumulation in MSNs,
our results clearly demonstrate that cell-autonomous tox-
icity of mhtt in striatal MSNs is not sufficient to elicit
robust motor deficits and striatal neuropathology in these
mice. These analyses demonstrate, for the first time, that
pathological cell-cell interactions are necessary for striatal
pathogenesis in a genetic mouse model of HD.
Cell-autonomous NMDA receptor dysfunction in the 
striatal model of HD
To further characterize similarities and differences among
models we assessed NMDA receptor function in acutely
dissociated striatal MSNs in all three models in mice at 6
months of age. First we examined membrane properties of
the dissociated neurons. The only significant change in
membrane properties occurred in the pan-neuronal
model in which membrane capacitance was smaller in the
transgenic cells (12.1 ± 0.6 pF in WTs versus 10.8 ± 0.6 pF
in transgenics; p < 0.05, t-test), suggesting a smaller neu-
ron size. There was no significant change in capacitance in
the cortical and striatal models. Input resistance was sim-
ilar in WT and transgenic cells in all three groups.
We then determined if there were changes in NMDA
receptor-mediated currents. Fig. 5 (top panel) shows typi-
cal currents evoked by application of NMDA in neurons
from mice in each group. In the absence of Mg2+, NMDA
current amplitudes and densities were dependent on
holding potential and decreased at -40 mV compared to -
70 mV in WT and transgenic cells in all 3 groups (ANOVA
followed by Bonferroni's t-test p < 0.001, Fig. 5, 2nd and
3rd panel). Co-application of 50 μM Mg2+ with 100 μM
NMDA significantly decreased currents in WT and trans-
genic cells in all groups (ANOVA followed by Bonferroni's
t-test p < 0.001, Fig. 5, bottom panel). In the pan-neuro-
nal model, 100 μM NMDA induced significantly smaller
peak currents in transgenic compared to WT cells at both
-70 and -40 mV holding potentials (ANOVA followed by
Bonferroni's t-test p < 0.05) (Fig. 5, 2nd panel). Current
densities also were significantly smaller in transgenic cells
but only at -70 mV (p < 0.01, Fig. 5, 3rd panel). In the pres-
ence of Mg2+, NMDA peak currents and densities were no
longer different between WT and transgenic cells, at either
holding potential (p > 0.05). However, the percent block
by Mg2+ was significantly smaller in transgenic compared
to WT cells at -70 and -40 mV (p < 0.05, Fig. 5, bottom
panel). In contrast to the pan-neuronal model, NMDA
peak currents and densities in the striatal model were
larger in transgenic compared to WT cells at -70 mV
(ANOVA followed by Bonferroni's t-test p < 0.05) (Fig. 5,
2nd and 3rd panels). The difference was not significant at -
40 mV. In the presence of 50 μM Mg2+, NMDA peak cur-
rents and densities were also significantly larger in trans-
genic cells (p < 0.01). Similar to the pan-neuronal model,Page 4 of 11
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70 and -40 mV (p < 0.05, Fig. 5, bottom panel). In the cor-
tical model, NMDA peak currents and densities were sim-
ilar in WT and transgenic cells and the effects of Mg2+
blockade were not different.
Discussion
To address the role of pathological cell-cell interactions in
striatal pathogenesis in HD mousemodels in vivo, we
developed a striatum-specific mouse model of HD which
expresses a neuropathological fragment of mhtt (mhtt-
exon1) selectively in striatal MSNs and in a subset of cor-
tical interneurons but not in the CPNs or other neurons in
the brain. This model reveals that striatal-specific expres-
sion of mhtt is sufficient to elicit cell-autonomous mhtt
nuclear accumulation and aggregation and NMDA recep-
tor dysfunction. However, cell-autonomous toxicity of
mhtt is insufficient to elicit progressive locomotor deficits
and significant striatal pathology including gliosis and
dark neuron degeneration, all of which are observed in
the pan-neuronal models of HD [27].
Responses to NMDA and their blockade by Mg2+ were
altered in mutant compared to WT mice in the pan-neuro-
nal and striatal model, but not in the cortical model. This
indicates that the presence of mhtt in CPNs alone does
not lead to changes in NMDA receptor-mediated currents
in the striatum. The changes in NMDA receptor function
in the pan-neuronal and striatal models were different,
with smaller NMDA currents in mutant cells from the
pan-neuronal model, and larger NMDA currents in
mutant cells from the striatal model. However, in both
models Mg2+ blockade of NMDA currents was reduced,
similar to effects in R6/2 mice of 15–40 days [31]. Previ-
ous studies on dissociated neurons in R6/2 mice have
shown both increases and decreases of glutamate recep-
tor-mediated currents depending on the age and the pro-
gression of the phenotype. In young R6/2 mice (15–40
days), NMDA and AMPA currents were increased, while in
Selective accumulation of mhtt aggregates in MSNs in the striatal modelFigure 2
Selective accumulation of mhtt aggregates in MSNs 
in the striatal model. (A) Double immunofluorescent 
staining with EM48 antibody [30] and anti-Darpp32 (a MSN 
marker) using 6 month old coronal brain sections from stri-
atal, cortical, and pan-neuronal models of HD. In both striatal 
and pan-neuronal models the vast majority of MSNs (>98%) 
have diffuse nuclear EM48 staining. Such a staining pattern is 
not present in the MSNs in the cortical model or WT mice at 
this age (data not shown for the WT). (B). Double immun-
ofluorescent staining with EM48 antibody and anti-GABA 
antibody (marker for cortical interneurons) in the striatal 
model of HD reveal that a few cells that accumulate nuclear 
EM48 staining in the cortex are GABA (+) interneurons 
(white arrows). Scale bars: 100 μm
Lack of progressive locomotor deficits in the striatal modelFigure 3
Lack of progressive locomotor deficits in the striatal 
model. In the striatal model, locomotor activity in the open 
field test is normal at 6 and 12 months, demonstrating cell-
autonomous accumulation of mhtt aggregates in MSNs are 
not sufficient to elicit a motor deficit.Page 5 of 11
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larly, biphasic changes for NMDA and AMPA currents
were observed in CPNs in young and older R6/2 mice
[33].
At the present time it is difficult to determine the mecha-
nisms underlying this complex set of electrophysiological
changes in different models at the same age. The presence
of mhtt in striatal neurons appears to be necessary to alter
Mg2+ sensitivity. This effect might be related to alterations
in NMDA receptor subunits [34-36]. The decrease in mag-
nitude of the NMDA current in the pan-neuronal model
might be related to changes in cortical inputs which have
been shown to occur in this and other transgenic mouse
models of HD [27,37]. In contrast, the increase in current
magnitude in the striatal model might reflect the possibil-
ity that alterations in the cortex no longer contribute to
striatal anomalies.
The core observations of the present study are consistent
with our prior analyses of the cortical model of HD. In
both cases, we found that mhtt aggregation is cell-auton-
omous, but cell-autonomous toxicity of mhtt in either
CPNs or MSNs is not sufficient to elicit robust regionally-
specific neuropathology and behavioral deficits as com-
pared to the pan-neuronal model. Thus, pathological cell-
cell interactions appear to contribute to neuronal toxicity
in both vulnerable neuronal populations in HD.
Although cell-type specific expression of mhtt-exon 1 is
insufficient to elicit robust pathology, our analyses did
provide evidence of cell-autonomous neuronal dysfunc-
tion. In the cortical model, we showed expression of mhtt-
exon1 in CPNs resulted in mild degenerative changes (i.e.
dark degenerating vacuoles in the CPNs under EM; see ref.
[27]); and in the striatal model, electrophysiological
recordings revealed cell-autonomous NMDA receptor-
mediated response changes in dissociated MSNs. Moreo-
ver, the regionally-specific expression of mhtt-exon 1
appears to be insufficient to elicit robust non-cell-autono-
mous toxicity in other brain regions. For example, selec-
tive expression of mhtt-exon1 in CPNs is not sufficient to
cause a significant striatal phenotype in the cortical
model. Thus, pathological cell-cell interactions are neces-
sary but not sufficient for cortical and striatal pathogene-
sis in HD. Based on these observations, we propose a
''two-hit'' hypothesis in which mhtt can elicit both cell-
autonomous toxicity and pathological cell-cell interac-
tions which are necessary for selective neuronal toxicity in
HD (Fig. 6)
Our analyses of the regional models of HD are consistent
with prior evidence supporting the possible role of cell-
cell interactions in HD striatal pathogenesis. First, excito-
toxicity is thought to contribute to striatal pathogenesis in
HD. The mechanisms underlying such toxicity are not
completely clear, but may include both cell-autonomous
mechanisms such as alteration in NMDA receptor func-
tion in the MSNs [17,33,38-40] or non-cell-autonomous
mechanisms, such as enhanced glutamate release from
CPNs [40-43] or reduced glutamate clearance [44-46].
Our in vitro electrophysiological analysis clearly confirms
prior results with R6/2 mice [23], and suggests that altered
Mg2+ blockade of NMDA receptors in striatal MSNs may
contribute to striatal excitotoxicity. Another mechanism
supporting cell-cell interactions in HD is the role of corti-
cal BDNF in striatal pathogenesis suggesting that the tran-
scription and axonal transport of BDNF is diminished in
HD models [25,47]. Since cortex-specific deletion of
BDNF is known to elicit progressive striatal degeneration
in mice [26], BNDF reduction will contribute to striatal
pathogenesis in HD. Finally, non-neuronal cells, particu-
larly astrocytes, are also affected in HD and HD mice.
Studies using primary cell culture demonstrate that astro-
cytes derived from R6/2 mice have reduced capacity to
transport glutamate, and thus cannot protect mutant neu-
rons from glutamate toxicity as well as astrocytes of WTs
[24]. Studies using mouse models of other neurodegener-
Lack of robust neuropathology in the striatal modelFigure 4
Lack of robust neuropathology in the striatal model. 
In the striatal model, we did not detect gliosis as indicated by 
the lack of GFAP staining in 12 month old transgenic mice 
(A) and in WT mice (12 months, B). Quantification of striatal 
gliosis [27] did not reveal any statistically significant differ-
ences between the two genotypes (C). (D) EM analyses did 
not reveal any degenerating dark neurons in the striatum (N 
= 2 per genotype). A representative healthy striatal neuron 
from the striatal model at 12 months of age is shown. Scale 
bars: A and B 100 μm; D 5 μm.Page 6 of 11
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Alterations in NMDA receptor-mediated currentsFigure 5
Alterations in NMDA receptor-mediated currents. Top panel. Representative traces of currents induced by 100 μM 
NMDA in the presence or absence of 50 μM Mg2+ at a holding potential of -70 mV. In the pan-neuronal model, the NMDA cur-
rent in the absence of Mg2+ is smaller in the transgenic (Tg) cell while in the presence of Mg2+, the current is similar to the WT. 
In the striatal model, the NMDA current in the presence or absence of Mg2+ is larger in the transgenic cell than in the WT cell. 
In the cortical model NMDA currents in the presence or absence of Mg2+ were similar in WT and transgenic cells. 2nd and 3rd 
Panels. Graphs showing mean peak currents (± SEM) and mean peak current densities (± SEM) evoked by 100 μM NMDA in 
the absence of Mg2+ in each model. In the pan-neuronal model, NMDA peak currents were significantly smaller in transgenic 
cells at -70 and -40 mV and current densities were significantly smaller at -70 mV only. In contrast, in the striatal model, NMDA 
peak currents were significantly larger in transgenic cells at -70 and -40 mV and current densities were significantly larger at -70 
mV only. In the cortical model, there were no differences in NMDA peak currents and current densities between WT and 
transgenic cells at any holding potential. Bottom Panel. Bar graphs showing mean percent block (± SEM) of NMDA currents by 
50 μM Mg2+. In the pan-neuronal and striatal models, Mg2+ block was significantly smaller in transgenic compared to WT cells 
at -70 and -40 mV. In the cortical model, there were no differences in Mg2+ block between WT and transgenic cells at any hold-
ing potential.
Molecular Neurodegeneration 2007, 2:8 http://www.molecularneurodegeneration.com/content/2/1/8ative disorders, such as amyotrophic lateral sclerosis [48],
frontotemporal dementia [49], synucleinopathy [50], and
spinocerebellar ataxia 7 (another polyQ disorder) [51],
provide in vivo genetic evidence that non-neuronal cells
may contribute to neurodegeneration. Thus, converging
evidence suggests pathological cell-cell interaction as a
common cellular mechanism in multiple neurodegenera-
tive disorders.
Our analyses of the striatal model of HD also indicate that
caution should be used when interpreting neurodegener-
ative phenotypes in HD cellular models over-expressing
pathogenic fragments of mhtt. These cellular models have
been particularly valuable for rapid dissection of molecu-
lar mechanisms underlying the mhtt toxicity. Since neuro-
degeneration in such models occurs rapidly in days and is
due to cell-autonomous toxicity of mhtt, and our striatal
model of HD demonstrates that cell-autonomous toxicity
of mhtt-exon1 in vivo is insufficient to elicit significant
neuropathology, the rapid neurodegenerative process
observed in cellular models may reflect different mecha-
nisms than the slow degenerative process which occurs in
the in vivo models. The latter may require pathological
cell-cell interactions. We suggest that the cellular models
are valuable for rapid identification of candidate molecu-
lar mechanisms underlying both cell-autonomous and
non-cell-autonomous toxicity of mhtt, and these mecha-
nisms should be validated in in vivo genetic models of HD.
Conclusion
We have developed a novel genetic mouse model in
which a neuropathogenic fragment of mhtt-exon1 is selec-
tively expressed in striatal MSNs and a subset of cortical
interneurons. We demonstrate that the striatal model of
HD exhibits cell-autonomous accumulation of nuclear
mhtt aggregates, and alterations in NMDA receptor func-
tion, but this model lacks robust striatal neuropathology
(i.e. gliosis and dark neuron neurodegeneration) and pro-
gressive motor deficits. Taken together these findings
emphasize that pathological cell-cell interactions are nec-




The RosaHD mouse is a conditional HD mouse model in
which expression of mhtt-exon1 with 103 glutamine
repeats is completely dependent on Cre-mediated exci-
sion of a transcription termination sequence flanked by
two Cre binding sites (LoxP) (Fig 1A). RosaHD mice were
bred with Dlx5/6-Cre mice [29] to generate the striatal
model that expresses mhtt in striatal MSNs and cortical
interneurons. The pan-neuronal and cortical models were
generated by crossing RosaHD mice with Nestin-Cre and
Emx-Cre mice as reported previously [27]. RosaHD mice
were maintained as 129Sv and C57BL/6 hybrids. Dlx5/6-
Cre mice were maintained on C56BL/6 background. The
male and female F1 mice from crosses between RosaHD
and Cre mice were used in the present experiments. Mice
were group housed in a clean facility with free access to
food and water. Animal breeding and experiment proto-
cols were in accordance with the National Institute of
Health Guidelines for use of live animals and approved by
the Animal Research Committee at UCLA.
Automatic Open Field Test
Twenty naïve transgenic and 22 WT littermates at 6
months of age and 15 transgenic and 14 WT littermates at
12 month were tested with an Automatic Open Field sys-
Schematics illustrating the two-hit hypothesis of neuropatho-gen sis in condi ional models of HDFigure 6
Schematics illustrating the two-hit hypothesis of neu-
ropathogenesis in conditional models of HD. Our cur-
rent analyses of the striatal model and our previous study of 
the cortical and pan-neuronal model of HD have shown that 
behavioral deficits and robust cortical and striatal neuropa-
thology are observed only when mhtt-exon1 is broadly 
expressed in the brain (pan-neuronal model). When mhtt-
exon1 only is expressed in one of the known vulnerable neu-
ronal populations, CPNs (cortical model) or striatal MSNs 
(striatal model), significant motor deficits or robust gliosis 
and degenerative changes did not occur despite cell-autono-
mous accumulation of mhtt aggregates. Thus, these findings 
rule out the cell-autonomous model which suggests expres-
sion of mhtt in the vulnerable neurons alone is sufficient to 
elicit robust neuropathology in that neuron (A). Since in both 
the cortical model [27] and in the striatal model, cell-autono-
mous expression of mhtt did exhibit evidence of neuronal 
dysfunction (i.e. degenerating lysosomes in the cortical model 
and electrophysiological changes in striatal model), the find-
ings also suggest a pure cell-cell interaction model (B) is also 
unlikely. Thus, our current data favor the two-hit hypothesis 
(C), which suggests both cell-autonomous toxicity and path-
ological cell-cell interaction synergistically contribute to neu-
ropathogenesis of the vulnerable cortical and striatal 
neurons.Page 8 of 11
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PA). A mouse was placed in an open field arena for 15
min during the dark phase of the 6:00 PM–6:00 AM dark-
light cycle. Locomotor activity and the proportion of time
spent in the center and margin areas were recorded and
calculated using the Tru Scan 99 Software.
Neuropathology
Transgenic and their WT littermates were transcardially
perfused with ice-cold 0.1 M phosphate buffer (PB, pH
7.2), followed by ice cold 4% paraformaldehyde with
0.2% glutaraldehyde in 0.1 M PB (pH 7.4). After 6 h post-
fix in 4% paraformaldehyde buffer as above, brains were
equilibrated with 30% sucrose by shaking at 4°C until the
brains sank to the bottom of the container. Thirty-five μm
coronal or saggital brain sections were cut using a Leica
CM 1850 cryostat and stored at -20°C. Free-floating sec-
tions were processed for immunohistochemistry staining
as described previously [27]. The following primary anti-
bodies were used: rabbit anti-human htt EM48 antibody
(1:300), mouse anti-GFAP antibody (1:10000, Sigma),
goat anti-mouse Darpp32 antibody (1:1000, Chemicon),
mouse anti-GABA (1: 1000, Sigma). EM48 and GFAP
immunostaining were visualized by using diaminobenzi-
dine as the chromogen (Pierce); Goat anti-rabbit Alexa
Fluor 488 (Molecular Probes) and goat anti-rabbit Texas-
red (DAKO), goat anti-mouse Alexa Flour 546 (Molecular
Probes) were used for EM48/Darpp32 and EM48/GABA
double immunofluorescent stainings, respectively. The
EM48/Darpp32 double immunofluorescence staining
was carried out by using the two step sequential method
after verification of antibody specificity in control sec-
tions. Briefly, brain sections were blocked with normal
goat serum and stained with EM48 antibody and Alexa
Fluor 488 secondary antibody. The sections were further
washed and blocked with normal goat serum, then
stained with Darpp32 antibody and Texas-red secondary
antibody. All steps in the second round of Darpp32
immunostaining were carried out in the dark. Quantita-
tive analyses of reactive gliosis were performed blind with
respect to genotype as described [27].
Electron Microscopy
Two 12 month-old pan-neuronal, cortical and striatal
model mice and their WT littermates were trancardially
perfused with ice-cold 0.1 M PB (pH 7.2), followed by ice
cold 2% paraformaldehyde with 2% glutaraldehyde in 0.1
M PB (pH 7.4). The brains were dissected out and
immersed in 0.1 M PB for 6 h. 100 μm sections were sliced
using a vibratome and treated with 1% osmic acid for 2 h.
After washing with 0.1 M PB, brain sections were dehy-
drated in ascending concentrations of ethanol and propyl-
ene oxide/Eponate 12(1:1) and embedded in Eponate
12(Ted Pella Inc., Redding, CA). Ultrathin sections (60
nm) were cut using a Leica UltracutS ultramicrotome.
Thin sections were counterstained with 5% aqueous ura-
nyl acetate for 5 min followed by Reynolds lead citrate for
5 min and examined using a Hitachi (Tokyo, Japan) H-
7500 electron microscope.
Electrophysiological Recordings
Mice 8–10 months of age were used. The following are the
numbers of mice and cells recorded from each group: 4
pan-neuronal model mice (14 cells) and 3 WT littermate
controls (10 cells), 4 striatal model mice (21 cells) and 4
WT littermate controls (19 cells), 4 cortical model mice
(25 cells) and 4 WT littermate controls (14 cells). Details
of procedures for acute dissociation and recording have
been published [31]. Briefly, mice were anesthetized with
halothane, transcardially perfused and decapitated. Brains
were dissected and sliced coronally and the dorsal part of
the striatum was dissected for acute dissociation of neu-
rons. Cells were recorded in an external Mg2+ free external
solution (in mM): 135 NaCl, 20 CsCl, 5 BaCl2, 10 glucose,
10 HEPES, 0.02 glycine and 0.0003 tetrodotoxin (TTX, pH
7.4, 300–310 mOsm). The external recording solution
contained Ba2+, instead of Ca2+, to minimize the influence
of Ca2+-mediated transduction systems. The presence of
Cs+ and TTX in the external solution blocked some volt-
age-gated K+ and Na+channels, respectively. The internal
pipette solution contained (in mM): 175 N-methyl-D-glu-
camine (NMDG), 40 HEPES, 2 MgCl2, 10 ethylene glycol-
bis (β-aminoethyl ether)-N, N, N', N'-tetraacetic acid
(EGTA), 12 phosphocreatine, 2 Na2ATP, 0.2 Na2GTP and
0.1 leupeptin (pH 7.2–7.3, 265–270 mOsm). Electrode
resistance was typically 4–5 MΩ in the bath. After seal rup-
ture, series resistance was compensated (70–90%) and
periodically monitored. Only data from cells for which
access resistance values were smaller than 20 MΩ were
included. Membrane capacitances and input resistances
were measured to compare membrane properties between
neurons from WT and transgenic mice. Drugs were
applied through an array of application capillaries posi-
tioned 500–600 μm from the cell using a pressure-driven
fast perfusion system. NMDA was applied for 3 sec every
10 sec. Responsiveness of cells to 100 μM NMDA and
their sensitivity to 50 μM Mg2+ were examined at two dif-
ferent holding potentials: -70 and -40 mV. The NMDA
receptor specific antagonist 2-amino-5-phosphonovaler-
ate was applied to confirm the specificity of NMDA-
induced currents (data not shown). To normalize to cell
size, peak current densities were measured by dividing
peak amplitude values by the capacitance of the cell.
Statistics
Values in the figures and text are presented as mean ±
standard error (SE). Appropriate student's t-tests alone
were used when two group means were compared. Elec-
trophysiological membrane properties and NMDA cur-
rent characteristics were compared using appropriate two-Page 9 of 11
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measure followed by multiple comparisons using Bonfer-
roni t-tests. Differences between means were considered
statistically significant if P < 0.05.
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